SOM.AU Somnomed Ltd
- Market cap
- AUD 63.7M
- P/E
- -
- P/B
- 1.34x
- ROE
- -5.6%
- Dividend yield
- -
- Fundamental score
- 2.3/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is SOM.AU undervalued?
Graham numberThe Graham number of Somnomed Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Somnomed Ltd fundamental analysis
10 of 21 checks passedROE 0/2
Low return on equity (-5.6%), below 10%.
ROA 1/1
Return on assets (-3.5%) is above the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (24.9%) is above the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 11.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (11.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.3x) is below the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Somnomed Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Somnomed Ltd
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment cent…
Full company profileSomnomed Ltd financial statements
Somnomed Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 49.3M | 52.4M | 58.9M | 57.3M | 62.7M | 72.6M | 83.6M | 91.7M | 111M | 115M |
| Gross Profit | 28.8M | 31.9M | 34.6M | 30.0M | 33.9M | 39.2M | 45.8M | 55.1M | 66.7M | 60.9M |
| Operating Income | -3.73M | 2.00M | 918K | -941K | -651K | -4.13M | -4.07M | -8.33M | 3.62M | 976K |
| EBITDA | -2.51M | 3.65M | 3.22M | 4.31M | 3.57M | 525K | 698K | -2.33M | 5.44M | 6.46M |
| Net Income | -3.34M | 2.32M | -39.4K | -1.12M | -1.19M | -4.44M | -8.00M | -12.2M | -3.46M | -2.65M |
| EPS | -0.06 | 0.04 | 0.00 | -0.02 | -0.01 | -0.05 | -0.10 | -0.10 | -0.02 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 41.2M | 45.7M | 34.8M | 61.7M | 56.2M | 58.1M | 62.5M | 69.8M | 81.0M | 75.0M |
| Total Liabilities | 10.3M | 12.9M | 16.9M | 27.9M | 24.0M | 30.3M | 40.1M | 24.8M | 34.6M | 27.6M |
| Shareholders' Equity | 32.2M | 36.1M | 17.8M | 33.8M | 32.2M | 27.8M | 22.4M | 45.0M | 46.4M | 47.4M |
| Cash & Short-term Investments | 14.2M | 13.4M | 7.70M | 30.2M | 21.1M | 15.6M | 12.0M | 16.2M | 17.3M | 17.2M |
| Total Debt | 123K | 1.44M | 3.60M | 15.5M | 8.91M | 12.0M | 23.5M | 6.72M | 8.03M | 5.46M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.68M | -9.47M | -6.55M | 5.19M | 2.71M | 1.86M | -3.88M | -6.33M | 7.78M | 8.28M |
| Capital Expenditure | 2.39M | 2.01M | 1.34M | 2.19M | 4.13M | 8.79M | 6.41M | 1.39M | 2.42M | 3.26M |
| Free Cash Flow | -5.07M | -11.5M | -7.89M | 3.00M | -1.43M | -6.93M | -10.3M | -7.72M | 5.36M | 5.02M |
| Ratios | ||||||||||
| ROE | -10.4% | 6.4% | -0.2% | -3.3% | -3.7% | -16.0% | -35.7% | -27.2% | -7.5% | -5.6% |
| ROA | -8.1% | 5.1% | -0.1% | -1.8% | -2.1% | -7.6% | -12.8% | -17.5% | -4.3% | -3.5% |
| Net Profit Margin | -6.8% | 4.4% | -0.1% | -2.0% | -1.9% | -6.1% | -9.6% | -13.4% | -3.1% | -2.3% |
| Debt to Equity | 0.00x | 0.04x | 0.20x | 0.46x | 0.28x | 0.43x | 1.05x | 0.15x | 0.17x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Somnomed Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | AUD 20.1M | 0.30 | - |
| 2019 | AUD 4.96M | 0.07 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Nov 27, 2009.
Who owns Somnomed Ltd
- Insiders 26.01%
- Institutions 63.37%
- Public & others 10.62%
- Shares outstanding 220M
- Free float 101M
Top funds holding SOM.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity International Small Cap Fund | 3.90M | 4.71% | - | Jan 2021 |
| DFA Asia Pacific Small Company Series | 25.2K | 0.03% | - | Jan 2021 |
Somnomed Ltd company profile
- Company name
- Somnomed Ltd
- Ticker
- SOM.AU
- ISIN
- AU000000SOM1
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 20 Clarke Street, Crows Nest, NSW, Australia, 2065
- Phone
- 61 2 9467 0400
- Website
- somnomed.com/au
About Somnomed Ltd
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Somnomed Ltd management
10- Ms. Karen Borg B.A.CEO & Executive Director
- Ms. Ye-Fei GuoChief Financial Officer
- Mr. Greg KnightChief Operating Officer
- Mr. David LewisChief Information Officer
- Mr. Nathan MinnichChief Marketing Officer
- Ms. Janice Hiskett-JonesChief People Officer
- Mr. Marco Van KleefPresident of Europe
- Mr. Keshan GunasingheChief Product Officer
- Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., SF FINCompany Secretary · born 1959
- Mr. Christopher BedfordVice President of Global Production and Product Development